$IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Clay Siegall
CEO
131
Employees
$23.61
Current Price
$2.03B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $4,393,024.30 | 201,050 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $5,484,686.30 | 256,050 | ||
| 1 month | Buys | 1 | 3 | $204,260.00 | 10,500 | 1:33.20 |
| Sells | 4 | 8 | $6,782,306.30 | 326,550 | ||
| 2 months | Buys | 1 | 4 | $307,760.00 | 15,500 | 1:22.04 |
| Sells | 4 | 8 | $6,782,306.30 | 326,550 | ||
| 3 months | Buys | 1 | 4 | $307,760.00 | 15,500 | 1:22.04 |
| Sells | 4 | 8 | $6,782,306.30 | 326,550 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Barchas Isaac Director | Sale | 24,335 | $23.33 | $567,735.55 | View Details |
| Jun 30, 2026 | Barchas Isaac Director | Sale | 101,050 | $21.12 | $2,134,176.00 | View Details |
| Jul 2, 2026 | Barchas Isaac Director | Sale | 75,665 | $22.35 | $1,691,112.75 | View Details |
| Jun 25, 2026 | Lechleider Robert Chief Medical Officer | Sale | 14,420 | $20.66 | $297,917.20 | View Details |
| Jun 25, 2026 | Lechleider Robert Chief Medical Officer | Sale | 40,580 | $19.56 | $793,744.80 | View Details |
| Jun 15, 2026 | Rosett Max Chief Financial Officer | Sale | 60,000 | $18.23 | $1,093,800.00 | View Details |
| Jun 5, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 1,000 | $19.27 | $19,270.00 | View Details |
| Jun 5, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 3,500 | $19.46 | $68,110.00 | View Details |
| Jun 5, 2026 | BIENAIME JEAN JACQUES Director | Sale | 500 | $19.44 | $9,720.00 | View Details |
| Jun 5, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 6,000 | $19.48 | $116,880.00 | View Details |
| Jun 5, 2026 | BIENAIME JEAN JACQUES Director | Sale | 10,000 | $19.41 | $194,100.00 | View Details |
| May 15, 2026 | BIENAIME JEAN JACQUES Director | Purchase | 5,000 | $20.70 | $103,500.00 | View Details |
14 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: